Run the Commercial Plan Every Week

Series · Commercial Planning · Part 5 of 5

Zenflow: the months between approval and the first commercial procedure

Zenflow reported FDA approval of the Zenflow Spring in December 2025. Its first commercial procedure took place on July 29, 2026, in a physician office in Winter Garden, Florida, and its September 8 announcement named three more urology practices that had recently performed first procedures, for four centers in total. [1] The release reports these dates and leaves the interval between them unexplained.

A weekly review can turn those dates into a measure. For each account, record the day a site agreed to start and the day of its first case, and ask what filled the time between them: contracting, training, supply or scheduling. The first procedure took place in a physician office, and the three later sites include a hospital-affiliated urology group and two independent practices. A team could track site type alongside site count, because each type may carry its own contracting and scheduling path.

Emanate: a plan that spans a year, reviewed in weeks

Emanate announced FDA 510(k) clearance for Perio PODS on September 17, 2026. The release lists several threads running together: manufacturing scale-up and commercial infrastructure ahead of a phased U.S. launch in 2027, a Launch Partner Program of practices that have joined, a 45-patient randomized trial at the ADA Forsyth Institute, and a larger multicenter trial underway through the McGuire Institute. [3]

Each thread could have its own owner and its own evidence date. A weekly review can ask how manufacturing capacity relates to the number of launch partners, how trial results change what clinicians and payers ask for, and how the partner list shapes where first cases occur. A plan with a launch date many months away still benefits from a weekly look, because any thread could move the date or the partner sequence. The company describes the clearance and launch plans; results from the larger trial are still to come, and a plan should list that as a dated open item.

Set decision rights before the meeting

List the decisions the weekly review can make and name who makes each one. A starting list:

• Account priority. Commercial lead decides, with input from the account owner.
• Support allocation. Field leader decides how clinical and technical help moves between accounts.
• Access and contracting path. Market-access lead decides, and the commercial lead confirms the effect on the forecast.
• Forecast change. Commercial operations lead proposes, and the executive owner approves.

These assignments are a proposed framework. Adjust them to the team you have.

Date the evidence and name the assumption owner

Every row in the review states when the evidence was last checked and who owns it. A trial result, a payer notice or a first-case date reads very differently six weeks later. When an evidence date passes your agreed age limit, the row goes to the top of the agenda as stale.

Define triggers that reopen a decision

Write the triggers down. Examples a team can adopt or change:

• Timing. An account moves from site agreement to first case more slowly than your lead-time measure.
• Supply. A capacity or delivery change affects the order of launch partners.
• Evidence. A trial readout or publication changes what a committee will ask for.
• Barrier. The same exception type appears in three accounts.
• Support. Company hours per case stay flat across an account's later cases.

Saluda Medical gives an example of a planned gate. On October 6, 2026, the company announced full U.S. commercial release of its CAP24 surgical paddle lead after a limited market release in selected centers, saying physicians had given positive feedback on performance and integration into practice. [2] A limited release is a decision point with a date. The weekly review can hold the criteria for moving from limited to full release, who decides, and what evidence from the selected centers will count. The announcement reports physician feedback and leaves center-level usage unreported, so a team would set its own usage criteria.

Run an account-centered review

Order the agenda by the account or milestone that moved, and avoid reading each department's report in turn. For each item, the owner states the evidence and its date, the team names the barrier, and one person records the next decision and its due date. Close by listing what changed in the plan and which forecast line moved.

Practical asset: the weekly commercial review template

A starting set of leading indicators, each paired with a decision the team can make when it moves:

Which row in your current plan carries an evidence date older than the limit you would set today?

Sources and evidence scope

Company releases checked October 13, 2026. Company statements are reported as company statements. The decision rights, triggers, indicators and template are a proposed operating framework. The sources describe approval, first cases, a limited-to-full release, clearance and launch plans, and leave weekly practices at these companies unreported.

1. Zenflow, "Zenflow Announces U.S. Commercialization Progress with Four Centers Completing Zenflow Spring Implant and Delivery System Procedures," GlobeNewswire, September 8, 2026.
2. Saluda Medical, "Saluda Medical Expands Access to First and Only FDA-Approved Closed-Loop Surgical Paddle Lead with Full US Commercial Release of CAP24," PR Newswire, October 6, 2026.
3. Emanate Biomedical, "Emanate Receives FDA 510(k) Clearance for Perio PODS," GlobeNewswire, September 17, 2026.

The full series

This is the final part. Part 1 set the ten workstreams, Part 2 chose the first buyer, Part 3 built the path to paid use, Part 4 made the second use repeatable and this part runs the plan weekly.